Figure 1: Median BLI Signal for Orthotopic 786-O (pMMP-LucNeo) Human Renal Carcinoma
Figure 2: Percent Survival for Orthotopic 786-O (pMMP-LucNeo) Human Renal Carcinoma
In an effort to address this unmet need, we have developed an orthotopic RCC model, 786-O (pMMP-LucNeo) through implantation into the sub-renal capsule. This cell line has been transfected with luciferase, which allows for disease and response monitoring through bioluminescence imaging (BLI). In 786-O tumor bearing mice, we evaluated the anti-cancer activity of sunitinib. While treatment failed to produce clinically relevant activity, there was a measurable difference between the control and the sunitinib treated groups. Over time, we have found that the tumor growth of this model is reproducible and reliable, making it useful for testing novel therapeutics targeting RCC.